4.7 Article

Type-I AIE photosensitizer triggered cascade catalysis system for tumor targeted therapy and postoperative recurrence suppression

Journal

CHEMICAL ENGINEERING JOURNAL
Volume 446, Issue -, Pages -

Publisher

ELSEVIER SCIENCE SA
DOI: 10.1016/j.cej.2022.136381

Keywords

Aggregation-induced emission; Single-atom nanozyme; Type-I photodynamic therapy; Continuous hydroxyl radical generation; Postoperative recurrence suppression

Funding

  1. Guangdong basic and Applied Basic Research Fund Regional Joint Fund Project (key project) [2020B1515120091]
  2. Shenzhen Basic Research Special (Natural Science Fund) basic research surface project [JCYJ20210324113006017]
  3. National Key Basic Researchand Development Projects [2017YFC1103601, 2017YFC1104102]

Ask authors/readers for more resources

In this study, a tumor exosome bionic cascade catalysis system was constructed to enhance the production of active oxygen species and effectively suppress tumor growth and induce tumor immunogenic cell death. The system shows great potential for clinical applications.
Aggregation-induced emission luminogens (AIEgens) based photodynamic therapy (PDT) has been emerging as a promising anti-cancer strategy. However, the short life span of many active oxygen species (ROS) reduces its therapeutic effect. Enhancing and maintaining the production of ROS in tumor cells remains a challenge. In this work, we constructed a tumor exosome bionic SAZs /AIEgens cascade catalysis system (CCS) for enhanced center dot OH generation and facilitating efficient tumor penetration. First, we prepared a Cu single atom nanozyme (Cu SAZs) with peroxidase activity, followed by coating with AIEgens absorbed tumor derived exosomes (TDE) to construct the CCS. The CCS system can penetrate tumor tissue after intravenous injection, and then TBP-2 generates center dot OH and hydrogen peroxide (H2O2) through type-1 PDT. Next, the H2O2 interacts with the Cu SAZs, resulting in the production of center dot OH in the tumor. The SGC 7901 tumor model experimental results revealed that the CCS systems significantly suppress tumor growth and efficiently cause tumor immunogenic cell death (ICD). CCS satisfies the requirement for enhanced and continuous generation of center dot OH, as well as compensates for the deficiency of H2O2 in SAZ-catalyzed therapy. More importantly, we found that CCS can effectively inhibit tumor recurrence in the CT26 recurrent mouse tumor model after surgery and has good clinical application potential.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available